SPEEDX
9.11.2020 14:02:13 CET | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive agreement to commercialise a host gene expression biomarker test for respiratory viral illness. Expression of the patented biomarker, IFI27, as discovered by NBMLHD Drs Anthony Maclean, Benjamin Tang and colleagues, is strongly correlated with disease progression in Influenza1 and COVID-19 patients2 . The commercial assay will be positioned to support clinicians facing difficult triage or patient management decisions, supporting risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201109005432/en/
“Host biomarkers are important indicators of a patient’s response to an infection,” said Professor Maclean, from the Nepean Hospital’s Intensive Care Unit. “Markers linked to viral specific immune responses, such as IFI27 – an interferon stimulating gene – are particularly informative. When they get switched on, it tells all the other immune cells to come and fight the virus. Levels of this specific marker, measured in the blood, have been shown to be directly correlated to progression of respiratory viral illness.”
The SpeeDx biomarker test utilises newly patented In SigniaTM technology that enhances the measurement of gene expression and is designed to run on standard laboratory equipment, allowing for expedited development and rapid adoption in high- and low-throughput hospital settings.
“The availability of a simple diagnostic test that can accurately differentiate viral from bacterial causes of pulmonary disease, using a single-gene host biomarker, would transform patient management,” said Dr. Charles Cartwright, SpeeDx VP of Scientific Affairs. “Coupled with a pathogen detection assay and other disease indicators, this test can not only stratify patients based on risk of adverse disease progression, changes in the level of biomarker over time can inform more accurate prognoses and guide ongoing patient management decisions.”
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
References
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
- https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005432/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Danube Properties Expands UK Presence with New London Office, Eyes Wider European Growth3.6.2026 11:34:00 CEST | Press release
Danube Properties, one of the UAE’s leading real estate developers, is set to strengthen its international presence with the launch of its new sales office in Central London. Located at 44 Brompton Road, Knightsbridge, SW3 1BW, the new office marks another milestone in the company’s growing expansion across the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260530149191/en/ Atif Farid, Head Business Development (UK); Rizwan Sajan, Founder and Chairman of Danube Group; and Adel Sajan, Managing Director of Danube Group, at the launch of Danube Properties' new sales office in Central London. (Photo: AETOSWire) The opening follows the successful launch of Danube Properties’ first UK office in Harrow two years ago, which established a strong connection with investors and homebuyers seeking premium Dubai real estate opportunities. Building on this momentum, the new Knightsbridge office aims to provide enhanced acce
Sensofusion Introduces its Aerospace Unit: Swift Surveillance Aircraft and Fennec Satellites3.6.2026 11:30:00 CEST | Press release
Finnish defence technology company Sensofusion Oy is expanding its operations from the ground to the air and into Earth orbit. As of today, the company's aviation and space business will operate under the name Sensofusion Aerospace.The unit's ongoing product development projects are the Sensofusion Swift surveillance aircraft and the company's first two satellite missions, Fennec-1 and Fennec-2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603447178/en/ With the Fennec-satellite program, Sensofusion's sensing capability extends into Earth orbit. Sensofusion Swift is a type-certified general aviation aircraft with integrated signals intelligence capability, radar and other advanced sensors. Unlike unmanned systems, Swift can operate in peacetime airspace near airports and population centres without separate exemptions. Sensofusion Swift is both an aircraft and a drone. It can be procured and operated either as a crewed g
Swedish Court Reschedules Publication of Judgment in PriceRunner Vs Google Antitrust Case3.6.2026 10:34:00 CEST | Press release
Klarna provides investor update Klarna Group plc (NYSE: KLAR) wishes to update investors that the Patent and Market Court in Stockholm, Sweden (Patent- och marknadsdomstolen) has postponed publication of its judgment in the antitrust damages proceedings brought by PriceRunner, a Klarna subsidiary, against Google. The Court has rescheduled publication of its judgment from 10 June to 26 June, 2026 at 11:00 CET. Important Notice The outcome of the proceedings is inherently uncertain. No assurance can be given that PriceRunner will succeed on liability or quantum. Any award would be subject to appeal by Google, to sharing arrangements with former PriceRunner shareholders and Klarna’s litigation funder, and to applicable taxation. The dollar amount of the claim should not be taken as an indication of any likely recovery. This announcement does not constitute a profit forecast. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable
Counterfeit Cigarettes Drive EU Illicit Market Above 10% for First Time Since 20143.6.2026 10:00:00 CEST | Press release
Illicit cigarettes reached 10.3% of EU consumption in 2025 (41.8 billion), with an estimated €16.7 billion in lost tax revenuesCounterfeits now lead the illicit market - accounting for 44% of EU illicit consumption (18.3 billion), up sharply year-on-year and displacing traditional East-to-West contraband flowsWestern Europe has the highest levels of illicit consumption, with France (41.4%), Belgium (24.8%), and the Netherlands (22.1%) among the most impacted. In France alone, counterfeit volumes reached nearly 10 billion cigarettes A new study detailing the scale of the illicit cigarette trade in the European Union (EU) shows that consumption of black-market cigarettes rose more than 7% year-on-year in 2025, reaching levels not seen in over a decade, with counterfeit cigarettes playing an increasingly significant role across member states. Philip Morris International (PMI) (NYSE: PM) reiterates its call for a coordinated response to illicit trade in Europe, built on evidence-based regu
Veth Propulsion by Twin Disc Unveiled New Streamline‑CRP™ at Maritime Industry Event3.6.2026 10:00:00 CEST | Press release
Product Reveal Took Place on June 2 Veth Propulsion by Twin Disc, a global leader in marine propulsion and maneuvering solutions, unveiled a new addition to its portfolio at Maritime Industry, a leading inland shipping tradeshow in the Netherlands, on June 2. Attendees experienced the debut firsthand. The new product, Streamline‑CRP™, is a major step forward in contra‑rotating propulsion technology. It was developed to meet the demand for higher efficiency, reduced emissions and better onboard comfort. It is purpose‑built for passenger cruise vessels and ferries. Streamline‑CRP delivers superior hydrodynamic performance, even in demanding, shallow‑water conditions. Streamline‑CRP is a next-generation azimuth thruster. It builds on Veth Propulsion’s long experience designing and making advanced propulsion systems. “Customers across the marine industry are demanding solutions that deliver both performance and efficiency,” said Bastiaan van Zuijlekom, Managing Director of Veth Propulsion.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom